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Purpose: Drug resistance is probably the greatest challenge to most malaria-control programmes. The 
goal of this study was to evaluate polymorphisms in parasite resistance gene markers, pfcft and dhfr, 
from falciparum malaria isolates collected in Adzopé City, Côte d’Ivoire in 2007.  
Methods: Blood samples were collected in filter paper from 72 children infected with Plasmodium 
falciparum living in Adzopé area. Plasmodium falciparum DNA was extracted and nested PCRs were 
performed using specific primers of pfcrt and dhfr-ts.  During the study, chloroquine and sulphadoxine-
pyrimethamine (which previously were the first- and second-line treatments, respectively, for malaria in 
Côte d’Ivoire) were not given to the enrolled children, having been withdrawn in 2004. 
Results: The results revealed the presence of the mutant-type pfcrt and dhfr-ts in 51 (62.2 %) and 29 
(35.4 %) samples, respectively. The mutant-type pfcrt alleles consisted of four single mutations 
(Met74/Asn75/Thr76) and 47 triple mutations (Ile74/Glu75/Thr76). However, the frequency distribution of 
mutations in dhfr-ts was 35.4 % for dhfr-Asn108, 17 % for dhfr-Ile51 and 21 % for dhfr-Arg59.  
Conclusion: The results of this study show high presence of chloroquine (CQ) resistance markers while 
for sulphadoxine-pyrimethamine (SP), a much lower prevalence was detected for the markers under 
study. Chloroquine remains an inadequate drug for malaria therapy in the study region. Furthermore, in 
spite of the official withdrawal of CQ and SP in favour of the arteminisin-based combinations (ACTs), it 
appears the population of this area continues to use the drugs via self-medication. 
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INTRODUCTION 
 
Malaria remains a major cause of morbidity 
and mortality in sub-Saharan Africa [1]. 
Worldwide malaria morbidity is estimated to 
be 300-500 million cases with about 1 million 
deaths each year, of which 90% occur in sub-
Saharan Africa [2]. The vast majority of 
deaths occur among children below five 
years of age and pregnant women, especially 
in remote rural areas with poor access to 
health services [3]. 
 
Malaria control is hampered by increasing 
spread of drug resistance. Although 
sulphadoxine-pyrimethamine (SP) has been 
abandoned as first- or second-line 
treatments, respectively, by most African 
malaria endemic countries in favour of 
artemisinin-based combination treatments 
(ACT), it is still used as intermittent 
preventive treatment during pregnancy (IPTp) 
[4]. However, SP resistance has been on the 
rise in the past few years and, although the 
link between molecular markers and 
treatment failure has not been firmly 
established, at least for pregnant women, 
these markers should be monitored. 
Pyrimethamine inhibits dihydrofolate 
reductase (DHFR), whereas sulfadoxine 
inhibits dihydropteroate synthetase (DHPS) 
[5]. 
 
Resistance to these drugs has been 
associated with single nucleotide 
polymorphisms (SNP) in the genes encoding 
DHFR and DHPS [6]. The key amino acid 
substitutions that confer falciparum malaria 
resistance to sulfadoxine and pyrimethamine 
are Ala437Gly and Lys540Glu or Ala437Gly 
in dihydropteroate synthase (DHPS), and 
Ser108Asn or Ser108Thr in dihydrofolate 
reductase (DHFR). In addition, dhfr mutations 
from Asn-51 to Ile-51 and Cys-59 to Arg-59 in 
association with Asn-108 were found to be 
associated with greater resistance to 
pyrimethamine [7]. 
 
In most countries, chloroquine (CQ) was, for 
many years, the first-line drug for malaria 
treatment. Unfortunately, resistance to this 
drug is nowadays widespread. However, in 
areas where drug pressure has been 
removed, the molecular markers linked to CQ 
drug resistance seem to disappear, indicating 
that local parasites are again sensitive to this 
drug [8,9]. 
 
It is, therefore, important to use molecular 
markers for monitoring drug resistance in a 
country and understand its spread as this 
may be important in designing strategies to 
guide the selection of drug resistant 
parasites. The spread of point mutations 
linked to drug resistance could be monitored 
by carrying out regular cross sectional 
surveys and then genotyping the samples 
from infected people. Molecular tools for the 
detection and identification of these SNPs, 
such as restriction fragment length 
polymorphism PCR (RFLP-PCR), are 
available [10]. CQ resistance is associated 
with a mutation in the Plasmodium falciparum 
chloroquine resistance transporter gene 
(K76T) [11]. This mutation is generally not 
isolated but is associated, depending on the 
geographical setting, with mutations at other 
codons, Cys72Ser, Met74Ile, Asn75Glu, 
Ala220Ser, Gln271Glu, Asn326Ser, 
Ile356Thr and Arg371Ile, the role of which is 
not well defined. 
 
In Côte d'Ivoire, until 2003, CQ and SP were 
used as first- and second-line drugs, 
respectively, for the treatment of 
uncomplicated malaria. ACT replaced CQ as 
the recommended first-line drug. SP remains 
recommended for IPT among pregnant 
women. A few years after, it was considered 
important to measure the prevalence of 
molecular markers of chloroquine and 
pyrimethamine resistance. Indeed, in Malawi, 
a sub-Saharan country, from 1992 to 2000, 
the prevalence of the CQ marker gradually 
decreased, disappearing completely by 2001 
after the withdrawal of CQ [12].  
 
The study aimed to evaluate SP and CQ 
resistance in falciparum malaria isolates, 
following withdrawal of these drugs, in 
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Adzopé, Côte d'Ivoire, using molecular 
characterization of the dhfr-ts and pfcrt 
genes, respectively. This city is considered 
as one of the sentinel sites of the national 




Blood collection area 
 
This study is a part of the cross-sectional 
surveys carried out in 2007 in Adzopé (lat. 
06°06´N and long. 03°51´W), situated in the 
south of Côte d'Ivoire, 108 km from Abidjan, 
the economic capital city. The rainy season 
occurs from March to July (average rainfall: 
1,789 mm/yr). The population was estimated 
at 43,821 inhabitants in 1998. Malaria is 
hyperendemic with no seasonal transmission. 
The most common vectors are Anopheles 
gambiae and Culex Quinquefasciatus. 
Plasmodium falciparum is the predominant 
malaria parasite.  
 
Blood samples used in this study were 
collected at random from 72 children aged 
between 6 months and 14 years, during a 
cross sectional survey in Adzopé. Fingerprick 
samples of capillary blood were collected 
from the selected children onto a filter paper 
strip (Isocode Stix®; Schleichler and Schuell, 
Ecquevilly, France). The samples were dried 
and stored at room temperature in an 
individual zip-lock polyethylene bags prior to 
DNA extraction and PCR studies. 
 
Plasmodium DNA extraction and 
amplification 
 
DNA was extracted from the dried blood on 
each filter-paper strip by rinsing each strip 
with 500 µL distilled water, immersing it in 75 
µL distilled water in a 0.5mL microtube and 
then incubating at 99 °C for 30 min [13]. 
 
The following mixture was prepared to a final 
volume of 50 µL: genomic DNA extracted as 
described above, 10 picomoles of each 
specific primer (obtained from Sigma-
Aldrich®), buffer (10 mM Tris, pH 8.3, 50 mM 
KCl, 1.5 mM MgCl2), 0.2 mM of 
deoxynucleoside triphosphates (mixture of 
dGTP, dATP, dTTP, and dCTP), and one unit 
of taq DNA polymerase (Roche Diagnostics, 
Meylan, France).  
 




dhfr-ts and TCRP-1 (5'CCG-TTA-ATA-ATA-
AAT-ACA-CGC-AG) /TCRP-2 (5'CGG-ATG-
TTA-CAA-AAC-TAT-AGT-TAC-C) for pfcrt. 
Due to the small quantity of DNA imbibed 
onto filter paper, nested PCR was necessary 
to obtain sufficient amount of amplified 
products for direct PCR sequencing or PCR-
RFLP. So, the first amplification was 
performed as described above, using 12.5 µL 
of DNA suspension. The secondary 
amplification was performed on the primary 
amplification product with internal primers: 
ST1L/DHFR-595R (5'CTG-GAA-AAA-ATA-
CAT-CAC-ATT-CAT-ATG-TAC) for dhfr-ts 
(595bp fragment) and TCDR-1 (5'TGT-GCT-
CAT-GTG-TTT-AAA-CTT) /TCDR-2 (5'CAA-
AAC-TAT-AGT-TAC-CAA-TTT-TG) for pfcrt 
(145 pb fragment). For the all running PCRs, 
the PTC-100 thermal cycler (MJ Research, 
Watertown, MA, USA) was programmed to 
carry out 30 cycles of 94 °C for 2 min (first 
cycle) or 1 min (rest of the cycle), 50°C x 1 
min (56 x 30 s for pfcrt), and 72 °C x 1min, 
followed by 72 °C x 10 min at the end of 30 
cycles. 
 
PCR-RFLP and sequencing of DNA 
fragments 
 
Pfcrt PCR products were digested by Apo I at 
50°C in the presence of NE buffer3 (50mM 
Tris-HCl, 10mM MgCl2, 100mM NaCl, 1mM 
DDT). As for dhfr-ts PCR products, they were 
submitted to the digestion of Alu I {(37 °C, NE 
buffer 2 (10mM Tris-HCl, 10mM MgCl2, 
50mM NaCl  and 1mM DTT)}. Apo I and Alu I 
cut the wild DNA fragments, haplotype Lys-
76 and Ser-108 of pfcrt and dhfr-ts genes, 
respectively. 
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However, in spite of the use of these 
enzymes, all the PCR products or DNA 
fragments from agarose gel (mixed alleles) 
were purified using the High Pure Kit 
purification product (Roche Diagnosis) and 
then sequenced in order to investigate 
additional mutations. 
 
Quality control and Data analysis 
 
A known DNA of P. falciparum was used as 
positive control in the PCR evaluation. The 
electropherograms of the purification PCR 
products sequenced by MWG-biotech (MWG-
Eurofin Operon) were analyzed by using 4 
peaks, Chromas Lite version 2.01 and ApE-A 
plasmid Editor V1.12 software.  
 
According to the haplotypes 74, 75 and 76 of 
pfcrt gene investigated, the wild-type pfcrt 
isolate was defined by the following 
combination: Met74/Asn75/Lys76, while for 
dhfr-ts, the allelic combination 
Ala16/Asn51/Cys59/Ser108/I164 defined the 
wild-type isolates. However, for each gene, 
the key amino-acid mutations that confer the 
resistance are Lys76 for pfcrt and Ser108 for 
dhfr-ts, respectively. 
Ethical review 
The study protocol was approved by the 
ethics committee of the Ivorian Ministry of 
Public Health and all legal parents or 
guardians of enrolled children gave their 




A total of 72 samples collected were 
successfully amplified. After PCR-RFLP 
running, according to only the haplotype 76 of 
pfcrt, 21 (29 %) wild type pfcrt Lys76, 41 (57 
%) mutant type pfcrt Thr76 and 10 (14 %), 
mixed population wild type/mutant type DNA 
fragments were obtained. For dhfr-ts, the 
outcome confirmed again the presence of 10 
wild type/mutant type (Ser108Asn) dhfr-ts 
isolates against 19 mutant-type dhfr-ts 
Asn108 (Table 1). 
Table 1: Distribution of DNA samples 
according to genetic profile 
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*- sM (single mutation): Thr76 for PFCRT and Asn108 for 
DHFR-TS 
- dM (double mutation): no double mutation was found in 
PFCRT; Ile51/Asn108 and Arg59/Asn108 in DHFR 
- tM (triple mutation): Ile74/Glu75/Thr76 in PFCRT and,  
Ile51/Arg59/Asn108 in DHFR-TS 
 
Due to the presence of the 10 mixed alleles, 
a total of 82 DNA fragments were sequenced 
instead of 72. Among them, 31 (37.8 %) were 
wild-type pfcrt (Met74/Asn75/Lys76) against 
51 (62.2 %) mutant type pfcrt. The mutant 
pfcrt haplotypes consisted of four single 
mutations (Met74/Asn75/Thr76) and 47 
triples mutations (Ile74/Glu75/Thr76). No 
double mutations were found (Table 1). The 
distribution of each PFCRT allele was: 57.3 
% (47) for both Ile74 Glu75, while 51 (62.2 
%) samples of DNA fragments were Thr76 
mutations (Table 2, Figure 1). 
 
Of the 82 samples of P. falciparum isolates 
investigated, 53 (64.6 %) had wild-type dhfr-
ts, while 29 (35.4 %) were mutant-type dhfr-
ts. They consisted of four single mutant-type 
samples (Asn51/Cys59/Asn108), nineteen 
double mutations distributed as follows: 
Ile51/Cys59/Asn108 (eight) and 
Asn51/Arg59/Asn108 (eleven). Six samples 
were triple mutant-type dhfr-ts 
Ile51/Arg59/Asn108 mutation (Table 2).  
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Table 2: Amino-acid residues obtained in DNA 
fragments in PFCRT and DHFR-TS of 
Plasmodium falciparum samples  
 
Amino-acids residues obtained and 
corresponding samples of P. falciparum 
PFCRT* DHFR-TS No. of samples 
74 75 76 51 59 108  
MNK NCS 23 
MNK NRN 2 
MNK ICN 2 
MNK IRN 4 
MNT NRN 2 
MNT IRN 2 
IET NCS 30 
IET NCN 4 
IET NRN 7 
IET ICN 6 
 
*The amino-acids residues transferred at different 
positions in PFCRT and DHFR-TS alleles are 
highlighted. For DHFR-TS, the haplotypes 16 and 164 
were wild-type in all samples 
 
 
Haplotypes 16 and 164 of the dhfr-ts in all 
DNA fragments were of the wild type. Any 
Thr108 allele in DHFR-TS was not detected 
in DNA fragments analyzed. The frequency 
distribution of the point mutations in dhfr 
among the mutant samples detected in the 
present study is shown in Figure 1. 
 
Among the 82 samples analysed in the study, 
59 (72 %) were affected by at least one point 





Drug resistance is probably the greatest 
challenge to most malaria control 
programmes. Given the limited resources for 
other malaria control measures, rational drug 
use is crucial, although economic constraints 
and the scarcity of the drug of choice 
hampers this. Close monitoring of the 
epidemiology and dynamics of drug 
resistance are necessary to implement 
measures to circumvent the problem and to 
allow Côte d’Ivoire’s National Malaria Control 
Programme to recommend the best available 
management of malaria. 
 
Like the in vitro tests, molecular markers of 
resistance might provide an early warning 


















Figure 1: Frequency distribution of key amino acids found in PFCRT and DHFR among the Plasmodium 
falciparum isolates in the area of Adzopé, Côte d’Ivoire 
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ing for guiding treatment efficacy studies [14]. 
Molecular markers are useful for monitoring 
the prevalence of mutations after a drug has 
been withdrawn or when a drug combination 
is used [12]. Our study was focused on 
molecular markers for chloroquine and 
pyrimethamine resistance. 
 
This study reveals a high frequency of drug 
resistance molecular markers for CQ (pfcrt 
Thr76; 62.2%). A similar study carried out in 
Abidjan, an area near Adzopé, reported 65 % 
of mutant type pfcrt Thr76 [15]. Previous 
studies conducted in Côte d’Ivoire and 
elsewhere in West Africa showed strong 
relationship between pfcrt Thr76 and 
therapeutic failure or in vitro chemoresistance 
of Plasmodium falciparum isolates to 
chloroquine [16,17]. This mutation is not 
generally isolated but is associated with other 
mutations at haplotypes 72, 74, 75, etc. In 
this study, most of the mutant-type pfcrt were 
triple mutant (Ile74/Glu75/Thr76) but the role 
of these complementary mutations is not well 
defined. A few years later, chloroquine was 
withdrawn from use due to high treatment 
failure rates (> 44 %). The proportion of pfcrt 
mutation (62 %) is reasonable evidence that 
there is a high level of chloroquine-resistant 
parasites circulating in this area. Thus, it 
would be too early to consider returning to 
the use of chloroquine alone as an 
antimalarial, although the drug itself is a safe 
and inexpensive, and ideally may be used in 
combination with another suitable antimalarial 
drug. In contrast, in Malawi, the first African 
country to replace chloroquine with SP, from 
1992 to 2000, the prevalence of the 
molecular marker of chloroquine gradually 
decreased, disappearing completely by 2001 
[12]. Today, chloroquine is once again highly 
efficacious in Malawi, 12 years after 
cessation of chloroquine use in that country 
[8]. 
 
For dhfr-ts gene, the mutation mainly affected 
codons 108 (35 %), 59 (21 %) and 51(17 %). 
Quadruple mutant, implying also the 
haplotype 16 or 164 which represents the 
most severe form of resistance and is 
responsible for high level of resistance to 
pyrimethamine, is at the present time not 
among the isolates of Côte d’Ivoire. These 
results are in agreement with others from 
western Africa, where prevalence of 
quadruple mutant has been observed [18]. A 
few rare strains carry the quadruple 
mutations in Africa, namely, Ghana, Kenya 
and Tanzania [19,20]. Elsewhere in the 
world, the Ile164Leu mutation is relatively 
uncommon but has been reported in 
Bangladesh, Bolivia, Brazil, Cambodia, 
China, India, Malaysia, Peru, Thailand and 
Viet Nam [21,22]. 
 
Although the frequency of mutation of dhfr-ts 
(Asn108, 35.4%) is relatively less than that 
seen with CQ in the same area (62.2 %), it is 
still alarming considering that the use of 
sulphadoxine-pyrimethamine as intermittent 
preventive treatment in pregnancy is 
unavoidable because suitable alternatives 
are not available yet. However, the 
prevalence of molecular markers of malarial 
organisms resistant to both chloroquine and 
pyrimethamine represented 48.8 % of the 
total samples. One of the reasons for this 
high level of the molecular markers of CQ 
and SP resistance is probably the wide usage 
of these drugs in Côte d’Ivoire in spite of their 
official replacement with ACT for the 
treatment of uncomplicated falciparum 
malaria. Maybe it is too early to evaluate the 
sensitivity of these drugs by monitoring the 
molecular markers for falciparum malaria 
resistance. In that case, it would be 
necessary to wait for some years before 




The study was the first molecular study 
carried out in this geographical area which is 
considered as one of the sentinel sites for 
malaria control programme of Côte d’ivoire. 
The results of the epidemiological study on 
the prevalence of genotypes associated with 
drug resistance, carried out in Adzopé, 
showed a high presence of chloroquine 
resistance markers, while for SP a lower 
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prevalence was detected. Since 2003, 
following the withdrawal of these anti-
malarials as first- and second-line drugs, 
respectively, the status of chloroquine and 
pyriméthamine-resistant parasite has not 
changed much in Adzopé with regard to the 
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